The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis

Samir Gupta, Susan L. Rosenkranz, Yoninah S. Cramer, Susan L. Koletar, Lynda A. Szczech, Valerianna Amorosa, Stephen D. Hall

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: To evaluate the pharmacokinetics and pharmacogenomics of efavirenz (EFV) and lopinavir/ritonavir (LPV/RTV) in HIV-infected persons requiring hemodialysis. Design: Prospective, observational study of HIV-infected hemodialysis patients receiving one 600 mg tablet daily of EFV (N = 13) or three 133.3/33.3 mg capsules twice daily of LPV/RTV (N= 13). Methods: Twenty-four-hour EFV and 12-h LPV/RTV pharmacokinetics were assessed. Geometric mean ratios were calculated using historical controls with normal renal function. The effects of several candidate gene polymorphisms were also explored. Results: The geometric mean [95% confidence interval (CI); percentage of coefficient of variation (% CV)] Cmin, Cmax, and area under the curve (AUC) for the EFV group were 1.81 μg/ml (0.93, 3.53; 103%), 5.04μg/ml (3.48, 7.29; 72%), and 71.5μgh/ml (43.2, 118.3; 93%), respectively. These parameters were 2.76μg/ml (1.86, 4.11; 53%), 8.45μg/ml (6.41, 11.15; 52%), and 69.67mu;g h/ml (55.6, 87.2; 37%) for LPV and 0.08 μg/ml (0.05, 0.14; 63%), 0.58 μg/ml (0.44, 0.76; 41%), and 3.74 μg h/ml (2.91, 4.80; 37%) for RTV. The AUC geometric mean ratios (90% CI) for EFV, LPV, and RTV were 132% (89, 197), 81% (67, 97), and 92% (76, 111), respectively. LPV Cmin was lower than expected in the hemodialysis group. Higher EFV concentrations were associated with the CYP2B6 516G7gt;T polymorphism. Conclusion: The pharmacokinetics of EFV and LPV/RTV in hemodialysis suggests that no dosing adjustments are necessary in treatment-naive patients. As HIV-infected hemodialysis patients are disproportionately black, the increased frequency of the CYP2B6 516G>T polymorphism may lead to higher EFV levels. The potentially lower LPV trough levels in this population suggest that LPV/RTV should be used with caution in protease-inhibitor-experienced patients.

Original languageEnglish
Pages (from-to)1919-1927
Number of pages9
JournalAIDS
Volume22
Issue number15
DOIs
StatePublished - 2008

Fingerprint

efavirenz
Lopinavir
Ritonavir
Pharmacogenetics
Renal Dialysis
Pharmacokinetics
HIV
Area Under Curve
Confidence Intervals
Protease Inhibitors
Tablets

Keywords

  • Dialysis
  • Efavirenz
  • HIV
  • Lopinavir
  • Pharmacogenomics
  • Pharmacokinetics
  • Renal failure
  • Ritonavir

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Gupta, S., Rosenkranz, S. L., Cramer, Y. S., Koletar, S. L., Szczech, L. A., Amorosa, V., & Hall, S. D. (2008). The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS, 22(15), 1919-1927. https://doi.org/10.1097/QAD.0b013e32830e011f

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. / Gupta, Samir; Rosenkranz, Susan L.; Cramer, Yoninah S.; Koletar, Susan L.; Szczech, Lynda A.; Amorosa, Valerianna; Hall, Stephen D.

In: AIDS, Vol. 22, No. 15, 2008, p. 1919-1927.

Research output: Contribution to journalArticle

Gupta, S, Rosenkranz, SL, Cramer, YS, Koletar, SL, Szczech, LA, Amorosa, V & Hall, SD 2008, 'The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis', AIDS, vol. 22, no. 15, pp. 1919-1927. https://doi.org/10.1097/QAD.0b013e32830e011f
Gupta, Samir ; Rosenkranz, Susan L. ; Cramer, Yoninah S. ; Koletar, Susan L. ; Szczech, Lynda A. ; Amorosa, Valerianna ; Hall, Stephen D. / The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. In: AIDS. 2008 ; Vol. 22, No. 15. pp. 1919-1927.
@article{5fa700f1848d47a7bc7ccc9573e22cdf,
title = "The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis",
abstract = "Lippincott Williams & Wilkins.",
keywords = "Dialysis, Efavirenz, HIV, Lopinavir, Pharmacogenomics, Pharmacokinetics, Renal failure, Ritonavir",
author = "Samir Gupta and Rosenkranz, {Susan L.} and Cramer, {Yoninah S.} and Koletar, {Susan L.} and Szczech, {Lynda A.} and Valerianna Amorosa and Hall, {Stephen D.}",
year = "2008",
doi = "10.1097/QAD.0b013e32830e011f",
language = "English",
volume = "22",
pages = "1919--1927",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis

AU - Gupta, Samir

AU - Rosenkranz, Susan L.

AU - Cramer, Yoninah S.

AU - Koletar, Susan L.

AU - Szczech, Lynda A.

AU - Amorosa, Valerianna

AU - Hall, Stephen D.

PY - 2008

Y1 - 2008

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - Dialysis

KW - Efavirenz

KW - HIV

KW - Lopinavir

KW - Pharmacogenomics

KW - Pharmacokinetics

KW - Renal failure

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=53549114197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549114197&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32830e011f

DO - 10.1097/QAD.0b013e32830e011f

M3 - Article

C2 - 18784455

AN - SCOPUS:53549114197

VL - 22

SP - 1919

EP - 1927

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 15

ER -